Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par pays : Latvia
Femme Max 99 ans
nct
MAJ Il y a 4 ans
Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms
This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.
Pays
Argentina
,
Australia
,
Finland
,
France
,
Germany
,
Korea, Republic of
,
Latvia
,
Netherlands
,
New Zealand
,
Poland
,
Slovenia
,
South Africa
,
Spain
,
Taiwan, Province of China
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
nct
MAJ Il y a 4 ans
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystiti...
Pays
Belgium
,
Czech Republic
,
Denmark
,
Germany
,
Latvia
,
Lithuania
,
Netherlands
,
Poland
,
Portugal
,
Romania
,
Russian Federation
,
Spain
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids
The purpose of this study is to focus on potential differences in the occurrence of new-onset Diabetes Mellitus (a glucose metabolism disorder) when two different regimens of immunosuppres...
Pays
Australia
,
Belgium
,
Colombia
,
Czech Republic
,
Estonia
,
Finland
,
France
,
Germany
,
Hungary
,
Italy
,
Korea, Republic of
,
Latvia
,
Lithuania
,
Mexico
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Romania
,
Russian Federation
,
Slovakia
,
Spain
,
Sweden
,
Switzerland
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modali...
Pays
Austria
,
Croatia
,
Czech Republic
,
Estonia
,
Finland
,
France
,
Germany
,
Hungary
,
Italy
,
Korea, Republic of
,
Latvia
,
Lithuania
,
Norway
,
Romania
,
Russian Federation
,
Slovakia
,
Spain
,
Sweden
,
Taiwan, Province of China
,
Ukraine
,
United States
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated i...
Pays
Australia
,
Canada
,
Estonia
,
Germany
,
Latvia
,
Lithuania
,
Russian Federation
,
Ukraine
,
United States
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. ...
Pays
Argentina
,
Canada
,
Denmark
,
Finland
,
France
,
Germany
,
Hungary
,
Italy
,
Latvia
,
Lithuania
,
Netherlands
,
Poland
,
Russian Federation
,
Slovakia
,
Spain
,
Sweden
,
Taiwan, Province of China
,
United States
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
An open ended study in which patients who completed the double-blind study CDP870-027 [NCT00152386] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Art...
Pays
Argentina
,
Australia
,
Belgium
,
Bulgaria
,
Canada
,
Chile
,
Croatia
,
Czech Republic
,
Estonia
,
Finland
,
France
,
Hungary
,
Israel
,
Latvia
,
Lithuania
,
Mexico
,
New Zealand
,
Russian Federation
,
Serbia
,
Slovakia
,
Ukraine
,
United States
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402 administered as a single intravenous infusion for the prevention of VTE in subjects undergoing total...
Pays
Austria
,
Belgium
,
Bulgaria
,
Hungary
,
Latvia
,
Netherlands
,
Poland
,
Russian Federation
,
Ukraine
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis
The purpose of this study is to estimate the systemic exposure to tacrolimus in infants with atopic dermatitis after repeated application of tacrolimus ointment. Efficacy of tacrolimus oin...
Pays
Canada
,
Finland
,
Ireland
,
Latvia
,
United Kingdom
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
nct
MAJ Il y a 4 ans
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires be...
Pays
Australia
,
Canada
,
Chile
,
Colombia
,
Finland
,
France
,
Germany
,
Greece
,
Italy
,
Latvia
,
Norway
,
Poland
,
Slovakia
,
Spain
,
Switzerland
,
United Kingdom
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant